A Downside Of Pandemic Preparedness: Wall Street May Not Value Government Contracts
Executive Summary
Human Genome Sciences founder William Haseltine says company's stock did not move following BARDA contract for its anthrax treatment; advises industry to forget about IP for COVID-19 products.
You may also be interested in...
AAM Offers Drug Manufacturing Repatriation Plan … For A Price
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
As Calls For Patent Sharing To Fight Pandemic Intensify, Manufacturing May Be Bigger Issue
Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.
Coronavirus Update: Moderna Lifted By BARDA funding, Europe Looks For Exit Strategy, Vaccine Funds
Plus: Moleculin hopes to move 2-DG prodrug into clinic, India progresses niche COVID-19 defenses and more.